Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Mol Cancer Res. 2014 Jan 24;12(4):607–621. doi: 10.1158/1541-7786.MCR-13-0469

Figure 6.

Figure 6

Figure 6

Figure 6

Effect of AnxA1 on incidence, types, differentiation and proliferation of glandular structures in LSCmed grafts (A–D). A, Chart depicting the incidence and type of glandular structures (prostatic glandular or acinar) scored in LSCmed untreated control, Ac2-26 treated and rAnxA1 treated grafts. B, Representative H&E images of the types of structures detected in rAnxA1 treated grafts. Black arrow indicates simple cuboidal structure. Magnification at 400×. Bar 100 µm. C, Tissue sections were analyzed by H&E for basic histology and IHC for expression of p63, CK8, AR and Ki67. Magnification at 400×. Bar 100 µm. D, Calculated percentage of p63+ cells and ratio of p63+ to CK8+ cells detected in the grafts. Potential to undergo de-differentiation in response to AnxA1 was assessed by increase in p63 expression compared to CK8. E, AnxA1 treated LSChi/med form more and larger glandular structures than controls. rAnxA1 treated LSCmed form more and larger acinar glandular structures than rAnxA1 treated LSChi and Ac2-26 treated LSCmed cells. Black bars represent left y-axis data and white bars represent right y-axis data. Statistical significance is indicated by *, P < 0.05; •, P < 0.01; **, P < 0.001.

HHS Vulnerability Disclosure